ABSTRACT
Neuromyelitis Optica and Multiple Sclerosis are idiopathic inflammatory demyelinating diseases of the central nervous system that currently are considered distinct autoimmune diseases, so differences in genetic susceptibility would be expected. This study aimed to investigate the HLA association with Neuromyelitis Optica by a systematic review with meta-analysis. The STROBE instrument guided research paper assessments. Thirteen papers published between 2009 and 2020 were eligible. 568 Neuromyelitis Optica patients, 41.4% Asians, 32.4% Latin Americans and 26.2% Europeans were analyzed. Only alleles of the DRB1 locus were genotyped in all studies. Neuromyelitis Optica patients have 2.46 more chances of having the DRB1*03 allelic group than controls. Ethnicity can influence genetic susceptibility. The main HLA association with Neuromyelitis Optica was the DRB1*03:01 allele in Western populations and with the DPB1*05:01 allele in Asia. Differences in the Multiple Sclerosis and Neuromyelitis Optica genetic susceptibility was confirmed in Afro descendants. The DRB1*03 allelic group associated with Neuromyelitis Optica has also been described in other systemic autoimmune diseases.
Subject(s)
HLA-DRB1 Chains/genetics , Multiple Sclerosis/genetics , Neuromyelitis Optica/genetics , Alleles , Asian People/genetics , Genetic Predisposition to Disease , Genotype , Humans , White People/geneticsABSTRACT
BACKGROUND: During the last two decades, neuromyelitis optica spectrum disorder (NMOSD) has undergone important changes, with new diagnostic markers and criteria, better recognition of clinical phenotypes, better disease prognosis and new therapeutic approaches. Consequently, management of NMOSD patients in Latin American (LATAM) has become more complex and challenging in clinical practice. In making these consensus recommendations, the aim was to review how the disease should be managed and treated among LATAM patients, in order to improve long-term outcomes in these populations. METHODS: A panel of LATAM neurologists who are experts in demyelinating diseases and dedicated to management and care of NMOSD patients gathered virtually during 2019 and 2020 to make consensus recommendations on management and treatment of NMOSD patients in LATAM. To achieve this consensus, the RAND/UCLA methodology for reaching formal consensus was used. RESULTS: The recommendations focused on diagnosis and differential diagnoses, disease prognosis, tailored treatment, identification of suboptimal treatment response and special circumstances management. They were based on published evidence and expert opinions. CONCLUSIONS: The recommendations of these consensus guidelines seek to optimize management and specific treatment of NMOSD patients in LATAM.
Subject(s)
Neuromyelitis Optica , Consensus , Humans , Latin America , Neurologists , Neuromyelitis Optica/diagnosis , Neuromyelitis Optica/therapy , PrognosisABSTRACT
The 5th International Porto Congress of Multiple Sclerosis took place between the 14th and 16th of February 2019 in Porto, Portugal. Its intensive programme covered a wide-range of themes-including many of the hot topics, challenges, pitfalls and yet unmet needs in the field of multiple sclerosis (MS)-led by a number of well-acknowledged world experts. This meeting review summarizes the talks that took place during the congress, which focussed on issues in MS as diverse as the development and challenges of progressive MS, epidemiology, differential diagnosis, medical management, molecular research and imaging tools.
ABSTRACT
BACKGROUND: A specific particularity of neurological diseases in Asia is the relative commonality of neuromyelitis optica (NMO) and Asian type MS (OSMS). Both conditions also occur in South American patients. The Brazilian population differs from the European and the Asian populations due to the mixture of ancestralities between European colonizers and African slaves. To better know the clinical characteristics of Brazilian patients with Asian type MS this study aimed to analyze the clinical, radiological and serological data that would help to distinguish between OSMS and NMO and clarify, in a Non-Asian population, if OSMS is an MS phenotype, an NMO spectrum disorder by 2015 classification, or a complement activating antibody to myelin oligodendrocyte glycoprotein (MOG-IgG) antibody-related disease. METHODS: We selected cases retrospectively with NMO and OSMS in the medical registry of patients with idiopathic inflammatory demyelinating diseases under follow-up since 1997 in Federal Hospital da Lagoa, the principal reference center for MS treatment in Rio de Janeiro, Brazil. OSMS has selective involvement of the optic nerve and spinal cord with no cerebral or cerebellar symptoms associated with small spinal cord lesions and negativity for the aquaporin-4 antibody (AQP4-IgG). NMO full-filled the revised criteria (2006) associated with longitudinally extensive transverse myelitis (LETM). We recorded the following data: ethnicity/skin color, neurologic impairment "at nadir" and "at recovery" of the index events (optic neuritis and transverse myelitis), long term disability, mortality, health quality of life scores by the SF-36 questionnaire, CSF IgG oligoclonal bands and serological AQP4-IgG and MOG-IgG antibodies tested by Cell-based assay. The last brain MRIs were classified as either satisfying or not satisfying MAGNIMS radiologic criteria for MS or typical or not typical for NMOSD. The new classification of NMO spectrum disorders (2015) was applied. RESULTS: Forty-one OSMS and 122 NMO cases were analyzed. OSMS affected mainly young white women, causing unilateral optic neuritis and partial myelitis with excellent recovery. After a mean disease duration of 20 years, 90% of the patients had free ambulation, and 70% had a mild disability or no disability. Only 7.2% presented a secondary progressive course, and no deaths occurred. All cases had negativity to AQP4-IgG and MOG-IgG biomarkers. 95% had resonance criteria for MS. OSMS differed from NMO by ethnicity, morbidity, and mortality: most were African descendants, with severe motor and visual dysfunction, and one third died. Only NMO cases full-filled the new NMOSD classification (52 AQP4-IgG positive, 29 AQP4-IgG negative, and 41 AQP4-IgG unknown). CONCLUSION: In Brazilian patients, OSMS and NMO are different immune-mediated diseases. OSMS is a milder MS phenotype.
Subject(s)
Aquaporin 4/immunology , Black People/ethnology , Multiple Sclerosis/ethnology , Myelin-Oligodendrocyte Glycoprotein/immunology , Neuromyelitis Optica/ethnology , Registries , White People/ethnology , Adolescent , Adult , Aged , Asian People/ethnology , Autoantibodies/blood , Brazil/ethnology , Child , Child, Preschool , Female , Humans , Longitudinal Studies , Male , Middle Aged , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Multiple Sclerosis/physiopathology , Neuromyelitis Optica/immunology , Neuromyelitis Optica/pathology , Neuromyelitis Optica/physiopathology , Phenotype , Severity of Illness Index , Young AdultABSTRACT
OBJECTIVE: Multiple sclerosis (MS) prevalence, in some cities in Brazil, was estimated and was found to range from 0.75 to 30.7/100,000. The reasons for such a large variation in rates of prevalence are not clear, but environment and genetics help to explain this phenomenon. METHODS: A cross-sectional study using three sources of case ascertainment to estimate the prevalence of MS in the city of Goiânia in December, 2015. RESULTS: A total of 318 MS patients was found after removing overlapping sources. The prevalence of MS was 22.4/100,000 population. CONCLUSION: Our study was the first in Goiás and the third in the midwest region, and we found a great increase in the prevalence of MS in the region. It is necessary to perform other studies using the same methodology for a more accurate evaluation of the true prevalence of MS in Brazil.
Subject(s)
Multiple Sclerosis/epidemiology , Brazil/epidemiology , Cross-Sectional Studies , Disabled Persons/statistics & numerical data , Female , Humans , Male , Prevalence , Retrospective Studies , Severity of Illness Index , Statistics, NonparametricABSTRACT
ABSTRACT Multiple sclerosis (MS) prevalence, in some cities in Brazil, was estimated and was found to range from 0.75 to 30.7/100,000. The reasons for such a large variation in rates of prevalence are not clear, but environment and genetics help to explain this phenomenon. Methods: A cross-sectional study using three sources of case ascertainment to estimate the prevalence of MS in the city of Goiânia in December, 2015. Results: A total of 318 MS patients was found after removing overlapping sources. The prevalence of MS was 22.4/100,000 population. Conclusion: Our study was the first in Goiás and the third in the midwest region, and we found a great increase in the prevalence of MS in the region. It is necessary to perform other studies using the same methodology for a more accurate evaluation of the true prevalence of MS in Brazil.
RESUMO A prevalência de esclerose múltipla (EM) no Brasil foi estimada em algumas cidades e foi encontrada entre 0,75 e 30,7 / 100.000. As razões para tal grande variação nas taxas de prevalência não são claras, mas existem aspectos ambientais e genéticos para explicar esse fenômeno. Métodos: Foram utilizadas três fontes de averiguação de casos para estimar a prevalência de esclerose múltipla (EM) no município de Goiânia em dezembro de 2015. Resultados: Foram encontrados 318 casos de EM, retirando as sobreposições de fontes. A prevalência foi de 22,4 / 100.000. Conclusão: Nosso estudo foi o primeiro em Goiás e o terceiro na Região Centro-Oeste, e encontrou um grande aumento na prevalência de EM na região. É necessário realizar outros estudos utilizando a mesma metodologia para uma melhor avaliação da real prevalência da EM no Brasil.
Subject(s)
Humans , Male , Female , Multiple Sclerosis/epidemiology , Severity of Illness Index , Brazil/epidemiology , Prevalence , Cross-Sectional Studies , Retrospective Studies , Disabled Persons/statistics & numerical data , Statistics, NonparametricABSTRACT
BACKGROUND: The HLA-DR15 extended haplotype HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 comprises the strongest genetic risk factor for multiple sclerosis (MS). The aim of this work was to investigate whether HLA-DR15 alleles were significantly associated with the susceptibility to MS familial forms (MSf) in an admixed Brazilian population. METHODS: Association analyses between DR15 and the clinical and demographic variables were made. RESULTS: We have genotyped 25 familial cases. The DR15 was detected in 11/25 (44%) of them and in none of controls (Pâ¯<â¯.00001). DR15 was significantly associated to a foreign ancestor background (Pâ¯=â¯.029) and later age of onset (Pâ¯=â¯.018).
Subject(s)
Genetic Predisposition to Disease/epidemiology , Genetic Predisposition to Disease/genetics , HLA-DR Serological Subtypes/genetics , Multiple Sclerosis/epidemiology , Multiple Sclerosis/genetics , Adult , Brazil/epidemiology , Cross-Sectional Studies , Female , HLA-DR Serological Subtypes/blood , Humans , Male , Middle Aged , Multiple Sclerosis/bloodABSTRACT
We report here one case of Zika virus (ZIKV) infection associated with auto-immunity directed against the central nervous system in a Brazilian woman who developed acute transverse myelitis 9 days after recovery from an acute episode of fever with generalized erythema. Imaging of the spinal cord showed an elongated area on the T1-T10 level with gadolinium uptake. The diagnostic of the ZIKV infection was confirmed by cerebrospinal fluid and serum analysis. This patient had serum positivity for autoantibodies against myelin oligodendrocyte glycoprotein (MOG), a specific antibody against the myelin sheath. We propose that a direct central nervous system infection by ZIKV could lead to a specific auto-immunity against MOG protein.
Subject(s)
Autoantibodies/biosynthesis , Erythema/immunology , Myelitis, Transverse/immunology , Spinal Cord/immunology , Zika Virus Infection/immunology , Zika Virus/pathogenicity , Acute Disease , Adult , Brazil , Contrast Media/administration & dosage , Erythema/complications , Erythema/diagnostic imaging , Erythema/virology , Female , Gadolinium/administration & dosage , Humans , Magnetic Resonance Imaging , Myelin Sheath/immunology , Myelin Sheath/pathology , Myelin Sheath/virology , Myelin-Oligodendrocyte Glycoprotein/antagonists & inhibitors , Myelin-Oligodendrocyte Glycoprotein/immunology , Myelitis, Transverse/diagnostic imaging , Myelitis, Transverse/etiology , Myelitis, Transverse/virology , Spinal Cord/diagnostic imaging , Spinal Cord/virology , Zika Virus/physiology , Zika Virus Infection/complications , Zika Virus Infection/diagnostic imaging , Zika Virus Infection/virologyABSTRACT
OBJECTIVE: Antibodies against Myelin Oligodendrocyte glycoprotein (MOG-Ab) have been investigated as potential biological marker for neuromyelitis optica (NMO) and high-risk syndromes (HR) negative for AQP4-Ab in populations with different ethnic background. We tested AQP4 and MOG antibodies in a Brazilian population with high African ethnic background. METHOD: The study population was composed of adult patients from Rio de Janeiro with inflammatory demyelinating diseases (new and old cases). Blood samples were sent blindly to test the AQP4 and MOG antibodies by CBA. The frequency of positive MOG-Ab was estimated in the NMOHR and the NMO spectrum disorders (NMOSD). A systematic review with meta-analysis assessed the frequency of MOG-Ab in Caucasians and non-Caucasians. RESULTS: 200 adult patients (52% Afro-Brazilian) 115 of them with NMOHR were tested. MOG antibodies were found in 5/68 negative cases of AQP4-Ab negative (7%). The criteria for NMOSD were fulfilled by 70 patients with NMOHR and none of them was positive for MOG-Ab. A low prevalence of MOG antibodies and a predominant phenotype of bilateral Optic Neuritis were found in most non-Caucasian patients. CONCLUSION: The low frequency of MOG Ab in patients from Rio de Janeiro and in other non-Caucasian populations suggests a racial/ancestral influence.
Subject(s)
Autoantibodies/blood , Demyelinating Diseases/blood , Demyelinating Diseases/ethnology , Ethnicity , Myelin-Oligodendrocyte Glycoprotein/immunology , Adolescent , Adult , Aged , Aquaporin 4/immunology , Brazil/ethnology , Child , Demyelinating Diseases/diagnostic imaging , Demyelinating Diseases/epidemiology , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Retrospective Studies , Statistics, Nonparametric , Young AdultABSTRACT
Objective Cognitive dysfunction is common in multiple sclerosis. The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) was developed to assess cognitive functions most-frequently impaired in multiple sclerosis. However, normative values are lacking in Brazil. Therefore, we aimed to provide continuous and discrete normative values for the BRB-N in a Brazilian population sample. Methods We recruited 285 healthy individuals from the community at 10 Brazilian sites and applied the BRB-N version A in 237 participants and version B in 48 participants. Continuous norms were calculated with multiple-regression analysis. Results Mean raw scores and the 5th percentile for each neuropsychological measure are provided, stratified by age and educational level. Healthy participants' raw scores were converted to scaled scores, which were regressed on age, sex and education, yielding equations that can be used to calculate predicted scores. Conclusion Our normative data allow a more widespread use of the BRB-N in clinical practice and research.
Subject(s)
Cognition/physiology , Neuropsychological Tests/standards , Adolescent , Adult , Age Factors , Aged , Brazil , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/physiopathology , Educational Status , Female , Humans , Male , Middle Aged , Multiple Sclerosis/physiopathology , Reference Standards , Reference Values , Regression Analysis , Reproducibility of Results , Sex Factors , Statistics, Nonparametric , Young AdultABSTRACT
ABSTRACT Objective Cognitive dysfunction is common in multiple sclerosis. The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) was developed to assess cognitive functions most-frequently impaired in multiple sclerosis. However, normative values are lacking in Brazil. Therefore, we aimed to provide continuous and discrete normative values for the BRB-N in a Brazilian population sample. Methods We recruited 285 healthy individuals from the community at 10 Brazilian sites and applied the BRB-N version A in 237 participants and version B in 48 participants. Continuous norms were calculated with multiple-regression analysis. Results Mean raw scores and the 5th percentile for each neuropsychological measure are provided, stratified by age and educational level. Healthy participants' raw scores were converted to scaled scores, which were regressed on age, sex and education, yielding equations that can be used to calculate predicted scores. Conclusion Our normative data allow a more widespread use of the BRB-N in clinical practice and research.
RESUMO Objetivo Disfunção cognitiva é comum em pacientes com esclerose múltipla. Por isto, a Brief Repeatable Battery of Neuropsychological Tests (BRB-N) foi desenvolvida para avaliar as funções cognitivas mais frequentemente alteradas na doença. Entretanto, estão faltando dados normativos desta bateria no Brasil. Assim, nosso objetivo foi fornecer valores normativos contínuos e discretos da BRB-N para a população brasileira. Métodos Foram recrutados 285 indivíduos sadios da comunidade em 10 centros do Brasil e aplicada a versão A em 237 e a versão B em 48 sujeitos. Normas contínuas foram calculadas com análise de regressão múltipla. Resultados Escores brutos médios e 5°percentil para cada subteste são fornecidos, estratificados por idade e nível educacional. Os escores brutos dos sujeitos sadios foram convertidos em escores de escalas e postos em regressão quanto a idade, sexo e educação, fornecendo equações que podem ser usadas para calcular escores previsíveis. Conclusão Nossos dados normativos permitem um uso mais amplo da BRB-N na prática clínica e na pesquisa, fornecendo normas para dados discretos e contínuos. Normas para dados discretos deveriam ser usadas com cuidado e escores demograficamente ajustados são geralmente preferidos quando interpretando dados neuropsicológicos.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Cognition/physiology , Neuropsychological Tests/standards , Reference Standards , Reference Values , Brazil , Sex Factors , Regression Analysis , Reproducibility of Results , Age Factors , Statistics, Nonparametric , Educational Status , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/physiopathology , Multiple Sclerosis/physiopathologyABSTRACT
OBJECTIVE: To describe the characteristics of 34 Brazilian NMO patients. To evaluate the contribution of the 2015 criteria to the diagnosis of NMO spectrum disorders (NMOSD) in 40 patients with longitudinal extensive transverse myelitis (LEMT). METHODS: This is a retrospective, descriptive and analytic study. RESULTS: Among NMO patients, there was a predominance of women, with onset in the fourth decade of life, and AQP4-IgG seropositivity in 73.5%. The diagnosis of NMOSD was established in 37.5% of LETM patients according to AQP4-IgG positivity and in 5% of LETM patients if the AQP4-IgG result was unknown. CONCLUSIONS: The characteristics of this series are similar to those of other Western populations. The AQP4-IgG testing assists in the diagnosis of NMOSD.
Subject(s)
Aquaporin 4/blood , Autoantibodies/blood , Neuromyelitis Optica/diagnosis , Adolescent , Adult , Aged , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Phenotype , Retrospective Studies , Young AdultABSTRACT
ABSTRACT The definition of neuromyelitis optica (NMO) is still evolving. In 2015, the International Panel for NMO Diagnosis was convened to develop revised diagnostic criteria. There have been few studies on NMO in the Brazilian population. Objective To describe the characteristics of 34 Brazilian NMO patients. To evaluate the contribution of the 2015 criteria to the diagnosis of NMO spectrum disorders (NMOSD) in 40 patients with longitudinal extensive transverse myelitis (LEMT). Methods This is a retrospective, descriptive and analytic study. Results Among NMO patients, there was a predominance of women, with onset in the fourth decade of life, and AQP4-IgG seropositivity in 73.5%. The diagnosis of NMOSD was established in 37.5% of LETM patients according to AQP4-IgG positivity and in 5% of LETM patients if the AQP4-IgG result was unknown. Conclusions The characteristics of this series are similar to those of other Western populations. The AQP4-IgG testing assists in the diagnosis of NMOSD.
RESUMO Neuromielite óptica (NMO) é um conceito em evolução. Em 2015, o Painel Internacional para o diagnóstico de NMO apresentou novos critérios diagnósticos. Poucos são os estudos em NMO na população brasileira. Objetivos Descrever as características de 34 casos brasileiros de NMO. Avaliar a contribuição dos critérios de 2015 para o diagnóstico de desordens do espectro NMO em 40 pacientes com mielite transversa longitudinal extensa (MTLE). Métodos Estudo retrospectivo, descritivo e analítico. Resultados Predomínio do sexo feminino, início na quarta década e anticorpo anti-AQP4 positivo em 73,5% dos casos de NMO. Diagnóstico de desordem do espectro NMO estabelecido em 37.5% dos casos de MTLE com positividade do anticorpo anti-AQP4 e em 5% se o resultado sorológico fosse desconhecido. Conclusões Esta série de casos de NMO tem características semelhantes às de outras séries ocidentais. A pesquisa do anticorpo anti-AQP4 é relevante para o diagnóstico das desordens do espectro da NMO.
Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Young Adult , Autoantibodies/blood , Neuromyelitis Optica/diagnosis , Aquaporin 4/blood , Phenotype , Enzyme-Linked Immunosorbent Assay , Retrospective StudiesABSTRACT
UNLABELLED: Clinically isolated syndrome may reflect the first symptom of Multiple Sclerosis. Though more prevalent in Caucasians, MS can also affect Afrodescendts. Modifying disease drugs can delay convertion to clinically defined multiple sclerosis, therefore, identify patients at a higher risk of convertion is important. However data of risk factors in racially mixed population are scarce. OBJECTIVES: To analyze predictor factors to the conversion from CIS to CDMS in a mixed race Brazilian cohort. PATIENTS AND METHODS: It is a prognostic observational retrospective study, in 122 patients from MS referential center at Hospital da Lagoa, Rio de Janeiro-Brazil. Demographic and clinical features, as well as MRI and cerebrospinal fluid data were analyzed. RESULTS: After five years follow-up 87.3% converted to CDMS. Regarding to median time of conversion, there was no difference between gender, race, age at onset, mono or polysymptomatic presentation. Cerebellar CIS significantly reduced time to second event; likewise sphincter impairment. Considering DMD, patients without treatment converted earlier. CONCLUSION: Ancestry did not influence conversion risk. Cerebellar and shpincter impairment as well as MRI criteria both Barkhof/Tintoré and Swanton were important predictors. In future studies it should be also analysed the risk factors of progression in mixed race populations.
Subject(s)
Demyelinating Diseases/epidemiology , Disease Progression , Multiple Sclerosis/epidemiology , Adolescent , Adult , Brazil/epidemiology , Child , Demyelinating Diseases/ethnology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multiple Sclerosis/ethnology , Risk Factors , Young AdultABSTRACT
Epidemiological studies of multiple sclerosis (MS) conducted in Latin America have revealed prevalence rates of this disease from low to medium. The aim of this study was to gather and analyze surveys on prevalence conducted in Brazil, noting its variability in different regions. Systematic review was held in electronic databases and manual search in abstracts concerning ECTRIMS, LACTRIMS and Brazilian Congress of Neurology. Nineteen studies made reference to prevalence rates that ranged from 1.36/100,000 to 27.2/100.000 inhabitants. More studies on the epidemiology of MS in Brazil will be needed for a better assessment of its prevalence and profile.
Subject(s)
Multiple Sclerosis/epidemiology , Brazil/epidemiology , Humans , PrevalenceABSTRACT
The idiopathic inflammatory demyelinating disease (IIDD) spectrum has been investigated among different populations, and the results have indicated a low relative frequency of neuromyelitis optica (NMO) among multiple sclerosis (MS) cases in whites (1.2%-1.5%), increasing in Mestizos (8%) and Africans (15.4%-27.5%) living in areas of low MS prevalence. South America (SA) was colonized by Europeans from the Iberian Peninsula, and their miscegenation with natives and Africans slaves resulted in significant racial mixing. The current study analyzed the IIDD spectrum in SA after accounting for the ethnic heterogeneity of its population. A cross-sectional multicenter study was performed. Only individuals followed in 2011 with a confirmed diagnosis of IIDD using new diagnostic criteria were considered eligible. Patients' demographic, clinical and laboratory data were collected. In all, 1,917 individuals from 22 MS centers were included (73.7% female, 63.0% white, 28.0% African, 7.0% Mestizo, and 0.2% Asian). The main disease categories and their associated frequencies were MS (76.9%), NMO (11.8%), other NMO syndromes (6.5%), CIS (3.5%), ADEM (1.0%), and acute encephalopathy (0.4%). Females predominated in all main categories. The white ethnicity also predominated, except in NMO. Except in ADEM, the disease onset occurred between 20 and 39 years old, early onset in 8.2% of all cases, and late onset occurred in 8.9%. The long-term morbidity after a mean disease time of 9.28±7.7 years was characterized by mild disability in all categories except in NMO, which was scored as moderate. Disease time among those with MS was positively correlated with the expanded disability status scale (EDSS) score (r=0.374; p=<0.001). This correlation was not observed in people with NMO or those with other NMO spectrum disorders (NMOSDs). Among patients with NMO, 83.2% showed a relapsing-remitting course, and 16.8% showed a monophasic course. The NMO-IgG antibody tested using indirect immunofluorescence (IIF) with a composite substrate of mouse tissues in 200 NMOSD cases was positive in people with NMO (95/162; 58.6%), longitudinally extensive transverse myelitis (10/30; 33.3%) and bilateral or recurrent optic neuritis (8/8; 100%). No association of NMO-IgG antibody positivity was found with gender, age at onset, ethnicity, early or late onset forms, disease course, or long-term severe disability. The relative frequency of NMO among relapsing-remitting MS (RRMS) + NMO cases in SA was 14.0%. Despite the high degree of miscegenation found in SA, MS affects three quarters of all patients with IIDD, mainly white young women who share similar clinical characteristics to those in Western populations in the northern hemisphere, with the exception of ethnicity; approximately one-third of all cases occur among non-white individuals. At the last assessment, the majority of RRMS patients showed mild disability, and the risk for secondary progression was significantly superior among those of African ethnicity. NMO comprises 11.8% of all IIDD cases in SA, affecting mostly young African-Brazilian women, evolving with a recurrent course and causing moderate or severe disability in both ethnic groups. The South-North gradient with increasing NMO and non-white individuals from Argentina, Paraguay, Brazil and Venezuela confirmed previous studies showing a higher frequency of NMO among non-white populations.
Subject(s)
Multiple Sclerosis/ethnology , Multiple Sclerosis/mortality , Neuromyelitis Optica/ethnology , Neuromyelitis Optica/mortality , Adolescent , Adult , Age Factors , Aged , Animals , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Infant , Male , Mice , Middle Aged , Multiple Sclerosis/diagnosis , Multiple Sclerosis/therapy , Neuromyelitis Optica/diagnosis , Neuromyelitis Optica/therapy , Sex Factors , South America/epidemiology , South America/ethnologyABSTRACT
BACKGROUND: There have been no clinical trials for approval of medications for treating multiple sclerosis in patients younger than age 18 years. All treatments are based on personal experience and data from open observational studies. Fingolimod is an oral drug for multiple sclerosis that has been shown to be efficient and safe in adults. The aim of our study is to describe patients with multiple sclerosis who started treatment with fingolimod before the age of 18 years. PARTICIPANTS AND METHODS: Seventeen patients treated with fingolimod were identified in the Brazilian database of children and adolescents with multiple sclerosis. The average time of use of the drug was 8.6 months. RESULTS: Fingolimod showed a good safety and efficacy profile in these patients, all of whom had very active multiple sclerosis. After starting treatment with fingolimod, only one patient had a relapse and a new lesion on magnetic resonance imaging. The patients' degree of disability did not progress. No major adverse events were reported in relation to the first dose of the drug, nor in the short- and medium-term treatment. No patient has been followed for longer than 18 months, thus limiting long-term conclusions. CONCLUSIONS: Off-label use of fingolimod in patients younger than age 18 years may be a good therapeutic option for multiple sclerosis control.
Subject(s)
Fingolimod Hydrochloride/therapeutic use , Immunosuppressive Agents/therapeutic use , Multiple Sclerosis/drug therapy , Adolescent , Brazil , Child , Child, Preschool , Disability Evaluation , Drug Prescriptions , Female , Follow-Up Studies , Humans , Magnetic Resonance Imaging , MaleABSTRACT
OBJECTIVE: To describe familial forms of demyelinating diseases from an MS referral center in Río de Janeiro State, Brazil. METHODS: A descriptive, cross-sectional study was done to identify familial IIDD cases in Hospital da Lagoa, a public hospital where 75% of patients with IIDD who live in Rio de Janeiro state, located in the Southeast region of Brazil, are referred. The diagnoses of all consecutive patients followed in 2011 were reviewed to apply new diagnostic criteria (Wingerchuk et al., 2008). The diagnosis of IIDD was confirmed based on clinical history, neurological examination, MRI of the skull and spinal cord, CSF analysis and investigation of IgG NMO antibodies. The cases that had at least one other relative with IIDD were selected for the study. RESULTS: Familial forms were found only in the multiple sclerosis (MS) and neuromyelitis optica syndrome (NMOSD) categories. 23 MS families were identified, 60.86% with first degree kinship. It has a Caucasian preponderance, 90% of whom were white. The frequency of early onset was 15% and 20% of the MSf cases have progressive primary course. CONCLUSION: The frequency of familial cases of IIDD was 6.12% among MS patients and 2.8% in NMO spectrum syndromes.
Subject(s)
Family Health , Multiple Sclerosis/epidemiology , Neuromyelitis Optica/epidemiology , Adolescent , Adult , Brazil/epidemiology , Cross-Sectional Studies , Disability Evaluation , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neurologic Examination , Young AdultABSTRACT
BACKGROUND: Motor dysfunction and fatigue are the most common impairments that are associated with multiple sclerosis (MS). Walk tests and scales demonstrate the presence of fatigue in patients with MS with different levels of disability. OBJECTIVE: To evaluate objective and subjective fatigue in MS patients without disability. METHODS: Were selected MS patients with relapsing remitting clinical course, from 18 to 55 years old and EDSS 0 to 1.5; controls were paired for age, gender, body mass index, and physical activity level. Fatigue caused by pulmonary diseases, anemia, diabetes, thyroid disease, psychiatry diseases (except depression), and orthopedic and rheumatologic diseases are excluded. All participants performed the 6-minute walk test (6MWT), the MS Functional Composite (MSFC), and completed the Modified Fatigue Impact Scale (MFIS) and the Beck Depression Inventory. A multivariate model was applied to identify the variables associated with fatigue. RESULTS: 54 individuals were selected (31 patients; 23 controls). In the MSFC and 6MWT, no significant difference was observed between the groups. A MFIS total score indicated fatigue in 35% of the patients, 42% in the physical domain, 25.8% in the cognitive domain, and 29% in the psychosocial domain, which differed from the controls in all comparisons. Fatigue was associated with MS, low-physical activity, and mood disorders. CONCLUSIONS: Fatigue occurs in patients with MS in the absence of motor dysfunction and is associated with the disease itself, the sedentary lifestyle, and mood disorders. The 6MWT is not useful to demonstrate motor fatigue in subjects without neurological disability.